CPT code 38240 – Allogeneic hematopoietic progenitor cell transplantation

Key takeaways

CPT code 38240 is billed per donor, so a transplant using cells from two documented donors supports two units.

38240 (allogeneic, donor cells) and 38241 (autologous, the patient’s own cells) are the most commonly confused codes in this family.

Most major commercial payers, including Aetna, BCBS and HealthNet, require prior authorization, and missing it is the leading denial reason.

CMS created a Comprehensive APC specifically for 38240 in the 2017 OPPS final rule, packaging most ancillary services on the same date.

CPT code 38240: Official descriptor and clinical overview

CPT code 38240 is defined by the American Medical Association as: Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor. The “per donor” language is the most billing-critical detail in the descriptor. Two donors used in a single transplant episode generate two billable units of 38240, provided each donor’s cell product is separately documented.

Hematopoietic progenitor cells are the parent blood-forming cells collected from a donor’s peripheral blood or bone marrow. The recipient first goes through a conditioning regimen of chemotherapy, radiation or both to clear the existing marrow. The donor HPCs are then infused intravenously and migrate to the bone marrow to restore blood cell production.

In billing terms, the allogeneic route means the cells come from someone other than the patient. That donor source is what separates 38240 from its autologous counterpart.

The procedure is performed in the inpatient setting for most patients, though outpatient transplants do occur at select high-volume centers. The site of service significantly affects payment, as discussed in the Medicare/OPPS section below.

CPT 38240 vs. CPT 38241: Key differences

CPT 38241 covers autologous HPC transplantation, where the patient’s own previously collected and stored cells are reinfused. The two codes are structurally similar but clinically and administratively distinct.

Misassigning 38241 when the record documents an allogeneic source is a frequent audit finding. The distinction depends entirely on whether the cells came from a matched sibling, matched unrelated donor (MUD), or other third-party source. HLA typing documentation in the record is what establishes allogeneic status for 38240.

Related codes in the bone marrow transplant CPT family

CPT code 38240 belongs to the 38240-38243 code range, the AMA subheading for transplantation and post-transplantation cellular infusion procedures. That range also includes 38243, the HPC boost code. Several codes in and around it are either separately reportable from 38240 or frequently confused with it.

OPPS C-APC packaging means 38207 and 38209 are bundled into the 38240 payment when billed on the same date at an outpatient hospital facility. In the inpatient setting, these companion codes are generally separately reportable under DRG payment rules. Check the current-year OPPS Addendum B before billing either one separately on an outpatient claim.

Together, the donor source, the donor count and the care setting decide almost every coding choice on a 38240 claim, as the path below shows.

ICD-10-CM diagnosis codes commonly paired with CPT 38240

The primary diagnosis must document a condition that medically necessitates an allogeneic approach. Payers use the ICD-10-CM code to confirm that 38240 (not 38241) was clinically appropriate. The table below lists the most common pairings.

Using an ICD-10-CM code that implies autologous intent is a common coding mismatch that triggers automatic denial. A multiple myeloma code on a record documenting an allogeneic procedure is the typical example. The diagnosis code must match the transplant type documented in the operative note.

Documentation requirements for CPT 38240

A complete medical record supporting a 38240 claim must contain all of the following. A claim missing any one of these elements can be denied or recovered in a post-payment audit. Ensuring medical billing compliance on high-cost oncology claims requires more rigorous pre-claim documentation review than most other procedure types.

• Operative or procedure note: Confirms the allogeneic source, infusion date, and the cell product administered. The note must explicitly state that donor cells were used, not the patient’s own cells.
• HLA typing report: Documents compatibility between donor and recipient. Required by most payers to confirm appropriateness of the allogeneic approach. A mismatched or undocumented HLA result is a post-payment audit flag.
• Conditioning regimen records: Chemotherapy and/or radiation records preceding the infusion date. These establish the transplant timeline and confirm the service was performed in the correct clinical context.
• Donor count documentation: When billing multiple units of 38240 (two donors), the record must document each donor’s cell product separately. A single procedure note referencing two donors without differentiating their contributions may not support two units.
• Diagnosis substantiating allogeneic approach: Clinical notes explaining why allogeneic rather than autologous transplantation was selected. This matters most for diagnoses where both approaches are used, such as certain lymphomas.
• Prior authorization approval: The auth number must be on the claim. Missing the auth number even when authorization was obtained will generate an automated denial at many payers.

A dedicated pre-claim checklist for 38240, reviewed by both the clinical team and the billing department, catches these misses before submission. Submitting a clean claim on the first pass matters here because appeals on high-cost oncology codes take longer to adjudicate than standard claims.

Prior authorization and payer requirements for HPC transplant

Nearly all major commercial payers require prior authorization for CPT code 38240, so it belongs at the start of your prior authorization process. Failure to obtain it before the transplant date accounts for the largest share of initial denials on these claims. Payer-specific policies to know include the following.

• Aetna (CPB 0190, Stem Cells for Hematopoietic Cell Transplant): Requires prior authorization and applies coverage criteria based on diagnosis, prior treatment, and performance status. Allogeneic transplant requests are reviewed against this Clinical Policy Bulletin.
• BCBS Florida (Medical Coverage Guidelines): Prior authorization required for all stem cell transplantation procedures. Coverage criteria include specific disease types and prior therapy requirements.
• HealthNet: HealthNet’s clinical policy for stem cell transplantation requires pre-authorization and documents coverage criteria by indication.
• Palmetto GBA (Medicare Jurisdiction J and M): Publishes a Local Coverage Determination governing Medicare coverage criteria for hematopoietic stem cell transplantation. Check the Palmetto GBA LCD database for the current effective version before submitting Medicare claims.

Not every payer requires prior authorization for 38240, but most commercial plans do, and the cost of these claims makes them a routine target. Automated claims management software can flag procedure codes with known PA requirements before the appointment is confirmed.

Medicare and OPPS billing for CPT code 38240

In the 2017 OPPS final rule, CMS established a Comprehensive Ambulatory Payment Classification (C-APC) specifically for CPT code 38240. This packaging approach changed how hospitals bill for outpatient allogeneic transplants under Medicare.

How C-APC packaging affects 38240 outpatient billing

Under the C-APC, CMS bundles the payment for most ancillary services provided on the same date as the 38240 infusion into a single prospective payment.

Services that fall within the C-APC’s scope cannot be separately billed on that date at the outpatient facility level. CMS updates this packaging logic every year in the OPPS Addendum. Check the current year’s C-APC assignments before billing companion codes alongside 38240.

Inpatient vs. outpatient billing pathways

Most allogeneic transplants are performed during an inpatient admission, where Medicare pays under the MS-DRG system. The hospital’s charge description master still captures the procedure as 38240. On the inpatient claim, though, the DRG drives the Medicare payment rather than the CPT code.

For outpatient transplants, the C-APC governs payment at the facility level, and 38240 is the primary HCPCS/CPT trigger for C-APC assignment. For the physician’s professional claim, the CMS Physician Fee Schedule lookup lists current RVU values and payment amounts by locality.

Allogeneic stem cell transplant reimbursement rates

Medicare reimbursement for CPT code 38240 depends on the care setting. The table below shows the payment mechanism in each setting and where to look up the current rate.

Medicare rates change annually. Before using any rate figure for contract negotiations or revenue projections, verify it against the current-year CMS CPT/HCPCS code list and OPPS Addendum.

Common CPT 38240 denial reasons and how to avoid them

CPT code 38240 denials cluster around a predictable set of causes. Good denial management workflows start by identifying which of these is the root cause before resubmitting.

When appealing a 38240 denial, include the operative note, HLA typing results, conditioning regimen records, and the authorization letter. Payers reviewing these appeals look for the same documentation elements listed in the checklist above.

The CARC and RARC denial codes on the initial electronic remittance advice show which element triggered the rejection. Match the resubmission’s supporting records to that code.

How claims management software prevents CPT 38240 denials

When the 38240 checklist lives in a spreadsheet and the auth number sits in an email, the missing piece usually surfaces with the denial. By then the appeal clock on a high-cost claim is already running.

Pabau, the practice management platform we build, keeps the authorization, the donor documentation and the claim in the same patient record. Its claims management tools flag procedure codes with known prior authorization requirements before the appointment is confirmed.

Professional claims then go out as 837P electronic claims through the Claim.MD clearinghouse integration, with eligibility checked before a high-cost procedure is scheduled. Your billing team spends its time on clean first submissions instead of months of appeals.

Stop 38240 denials before the claim goes out

Pabau’s claims management tools track prior authorization status, flag high-risk codes like CPT 38240 before submission, and send clean claims through the Claim.MD clearinghouse integration.

Book a demo

Conclusion

The coding rules for CPT code 38240 are settled. Denials come from process. The usual culprits are an auth number left off the claim, a note that never says “allogeneic”, or one unit billed for two donors.

Build the pre-claim checklist into the transplant schedule itself, so the authorization and donor documentation are confirmed before the infusion date. Then pull last quarter’s 38240 denials and fix the step behind the most common CARC first.

The trade-off is a few extra minutes per case before submission, set against months of appeals on a high-cost transplant claim. Book a demo to see how Pabau flags prior authorization and documentation requirements on 38240 claims before they go out.

Continue your research

How does the Claim.MD clearinghouse integration work? Claim.MD clearinghouse guide explains the EDI transaction sets, payer enrollment process, and ERA reconciliation workflow supported through Pabau.

What should a clean 38240 claim include? Medical superbill guide walks through the required fields and documentation elements that support accurate billing for complex procedures.

Weighing tools to manage transplant authorizations? Prior authorization software compares the options for tracking requests, approvals and auth numbers in one place.

Want to confirm coverage before the infusion date? Insurance eligibility verification explains what to check before a high-cost procedure is scheduled.

Frequently asked questions